CD81 sequence and susceptibility to hepatitis C infection

Journal of Medical Virology

Volumn 86, Issue 1, 2014, Pages 162-168

  Houldsworth, Annwyne ^a   Metzner, Magdalena M ^a,b   Demaine, Andrew ^a   Hodgkinson, Andrea ^a   Kaminski, Edward ^b   Cramp, Matthew ^b  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

CD81; E2 binding; Exposed but uninfected patients; HCV; Large extracellular loop; Spontaneous viral clearance

Indexed keywords

CD81 ANTIGEN; COMPLEMENTARY DNA; GENOMIC DNA; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE PREDISPOSITION; DNA EXTRACTION; EXON; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HEPATITIS C; HIGH RISK PATIENT; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; VIRAL CLEARANCE;

HEPATITIS C VIRUS;

CD81; E2-BINDING; EXPOSED BUT UNINFECTED PATIENTS; HCV; LARGE EXTRACELLULAR LOOP; SPONTANEOUS VIRAL CLEARANCE;

ADULT; AMINO ACID SEQUENCE; ANTIGENS, CD81; BASE SEQUENCE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA;

EID: 84887825110     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23726     Document Type: Article

References (29)

1. Alter H. 1999. Discovery of non-A, non-B hepatitis and identification of its etiology. Am J Med 107:16S-20S.
2. Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, Emerson SU, Cosset FL, Purcell RH, 2003. In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 100:14199-14204.
3. Chen Z, Zhu Y, Ren Y, Tong Y, Hua X, Zhu F, Huang L, Liu Y, Luo Y, Lu W, Zhao P, Qi Z. 2011. Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement. PLoS ONE 19:6.
4. Cole G, Coleman N, Soilleux E. 2004. HCV and HIV binding lectin, DC-SIGNR, is expressed at all stages of HCV induced liver disease. J Clin Pathol 57:79-80.
5. Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R, Naoumov NV. 1999. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut 44:424-429.
6. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abrignani S, Valiante NM. 2002. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195:35-41.
7. Deng J, Dekruyff RH, Freeman GJ, Umetsu DT, Levy S, 2002. Critical role of CD81 in cognate T-B cell interactions leading to Th2 responses. Int Immunol 14:513-523.
8. Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoël M, Keck ZY, Foung SK, Zeisel MB, Stoll-Keller F, Baumert TF. 2012. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 10:223-233.
9. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. 2005. Intrahepatic and peripheral blood virus-specific cytotoxic T lymphocyte activity is associated with a response to combination IFN-alpha and ribavirin treatment among patients with chronic hepatitis C virus infection. J Viral Hepat 12:125-129.
10. Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC. 2003. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA 100:4498-4503.
11. Hennig BJ, Hellier S, Frodsham AJ, Zhang L, Klenerman P, Knapp S, Wright M, Thomas HC, Thursz M, Hill AV. 2002. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 3:359-367.
12. Horne, JA, Clements, AJ, Drennan, P, Stein, K, Cramp, ME. 2004. Screening for hepatitis C virus in the Dartmoor prison population: An observational study. J Public Health 26:372-375.
13. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2:1240-1243.
14. Itakura J, Nagayama K, Enomoto N, Sakamoto N, Tazawa J, Izumi N, Marumo F, Sato C. 2001. CD81 nucleotide mutation in hepatocellular carcinoma and lack of CD81 polymorphism in patients at stages of hepatitis C virus infection. J Med Virol 63:22-28.
15. Kronenberger B, Sarrazin C, Hofmann WP, von Wagner M, Herrmann E, Welsch C, Elez R, Ruster B, Piiper A, Zeuzem S. 2004. Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression. J Viral Hepat 11:310-318.
16. Levy S, Shoham T. 2005. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol 5:136-148.
17. Levy S, Todd SC, Maecker HT. 1998. CD81 (TAPA-1): A molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 16:89-109.
18. Masciopinto F, Campagnoli S, Abrignani S, Uematsu Y, Pileri P. 2001. The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor. Virus Res 80:1-10.
19. Miyazaki T, Muller U, Campbell KS. 1997. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J 16:4217-4225.
20. Nattermann J, Nischalke HD, Feldmann G, Ahlenstiel G, Sauerbruch T, Spengler U. 2004. Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. J Viral Hepat 11:519-526.
21. Oren R, Takahashi S, Doss C, Levy R, Levy S. 1990. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol 10:4007-4015.
22. Roccasecca R, Ansuini H, Vitelli A, Meola A, Scarselli E, Acali S, Pezzanera M, Ercole BB, McKeating J, Yagnik A, Lahm A, Tramontano A, Cortese R, Nicosia A. 2003. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol 77:1856-1867.
23. Roque-Cuéllar MC, Sánchez B, García-Lozano JR, Garrido-Serrano A, Sayago M, Praena-Fernández JM, Núñez-Roldán A, Aguilar-Reina J. 2012. Expression of CD81, SR-BI and LDLR in lymphocytes and monocytes from patients with classic and occult hepatitis C virus infection. J Med Virol 84:1727-1736.
24. Silvie O, Rubinstein E, Franetich JF, Prenant M, Belnoue E, Renia L, Hannoun L, Eling W, Levy S, Boucheix C, Mazier D. 2003. Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat Med 9:93-96.
25. Tarrant JM, Robb L, van Spriel AB, Wright MD, 2003. Tetraspanins: Molecular organisers of the leukocyte surface. Trends Immunol 24:610-617.
26. Wack A, Soldaini E, Tseng C, Nuti S, Klimpel G, Abrignani S. 2001. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol 31:166-175.
27. Weng WK, Levy S. 2003. Hepatitis C virus (HCV) and lymphomagenesis. Leuk Lymphoma 44:1113-1120.
28. Yamada E, Montoya M, Schuettler CG, Hickling TP, Tarr AW, Vitelli A, Dubuisson J, Patel AH, Ball JK, Borrow P. 2005. Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets. J Gen Virol 86:2507-2512.
29. Zhang S, Kodys K, Babcock GJ, Szabo G. 2012. CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of HCV-infected cells and induction of IFNα. Hepatology 10:1002.